J&J Cuts Deal With US Over Risperdal Marketing Fraud
Johnson & Johnson revealed Tuesday that it had reached an agreement in principle that may resolve a single misdemeanor criminal charge over its marketing practices for antipsychotic drug Risperdal....To view the full article, register now.
Already a subscriber? Click here to view full article